· NASDAQ · USD · Data as of 2026-07-30
AUM
$1.07B
Expense ratio
0.35%
Yield
0.00%
YTD return
+15.15%
Last price
$9.55
Thematic Sector · Coverage 75% · medium
Today
42.3
Outlook
48.3
Block A (composite-derived)
50.4
Block C (market behavior)
37.1
Today overlay (Block D)
0.0
Outlook overlay (Block D)
0.0
today_score = clip(0,100, 50 + 0.15·(A−50) + 0.60·(C−50) + D_today). Block B (holdings rollup) is in Phase 3 development; β=0 caps the natural range at ~12.5–87.5 in Preview v0.9. Formula version tide-etf-v1.0.0.
50.4
Coverage 75% · medium
Liquidity
72.2
Expenses
80.0
Performance
45.3
Volatility
42.8
Dividend
2.9
Concentration
40.0
Smart Money
—
Activist
—
Formula version composite-v1.0.0. Axes hover to see why a sub-score is missing.
Principal Healthcare Innovators ETF (BTEC) is an exchange-traded fund from Principal Funds in the Mixed asset class. Launched in 2016. Assets under management: 878,952,576.
The fund tracks the Nasdaq Biotechnology Index.
Bullish Whales composite rating: 50 out of 100. Evidence coverage 75% across 6 of 8 axes. Strongest axes: expenses, liquidity, performance.
Annualized one-year realized volatility 19%, classified moderate. Weakest axes: dividend, concentration.
Top-10 weight 0%, diversified, led by AMGN.
etf_composite_score_current · composite_score, concentration_score, confidence, coverage_pct, dividend_score, expenses_score, liquidity_score, performance_scoreetf_holdings_top10 · holding_symbol, weightetf_universe · asset_class, aum_usd, benchmark, benchmark_provider, fund_type, inception_date, issuer, name, replication_method, ticker, volatility_1yiShares Nasdaq US Biotechnology UCITS ETF is an exchange-traded fund that seeks to track the performance of the Nasdaq Biotechnology Index, comprising Nasdaq-listed companies engaged in biomedical research to develop new treatments and cures for human diseases. Managed by BlackRock under the iShares brand and domiciled in Ireland, this UCITS-compliant ETF provides diversified exposure to the U.S. biotechnology and pharmaceutical sectors, adhering to strict EU regulations including the 5/10/40 diversification rule, liquidity requirements, and independent asset custody for investor protection. Launched on October 19, 2017, it employs a physical replication strategy in a long-only, accumulating format, reinvesting dividends to support compound growth without distributions. With a total expense ratio of 0.35% p.a. and a fund size exceeding EUR 781 million, it offers targeted access to innovative biotech firms driving advancements in healthcare, while remaining unhedged against currency fluctuations in its USD base. This ETF plays a key role in enabling European investors to participate in the dynamic biotechnology market through a transparent, regulated vehicle.
30-day change
$171.93M
90-day change
—
Current AUM: $1,066,400,704. AUM change is computed from rolling daily fundamentals snapshots; it reflects total net-asset deltas (creations/redemptions + market value moves), not pure share creations.
Fund documents (fact sheets, prospectuses, semi-annual reports) for BTEC are coming soon. The BW fund-document archive will surface PDFs alongside a metadata index for searchability.